![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » LAUNCH OF MACROFLUX CORPORATION IN $75 MILLION SPIN-OUT FROM JOHNSON & JOHNSON
LAUNCH OF MACROFLUX CORPORATION IN $75 MILLION SPIN-OUT FROM JOHNSON & JOHNSON
Macroflux Corporation has raised $75 million in an equity financing to create a new transdermal drug development company. Originally a group within ALZA Corporation, The Macroflux Corporation spin-out is being led by Nomura Phase4 Ventures, a specialist investor in healthcare. The syndicate includes significant investments from New Enterprise Associates (NEA) and funds managed by HBM Partners. The $75M financing will enable the company to progress several product opportunities through clinical development. ALZA Corporation, a wholly owned subsidiary of Johnson & Johnson, will retain an equity stake in the venture.
BioSpace (http://www.biospace.com/news_story.aspx?StoryID=32590&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct